Core Viewpoint - The sentiment in the market can be unpredictable, especially when leading companies in the sector are trading at valuations significantly higher than historical averages, leading to increased volatility [1]. Group 1 - The current trading situation of Stryker indicates that it is valued well above historical norms, which may contribute to market volatility [1].

Group 1 - The sentiment in the market can be unpredictable, especially when sector leaders are trading at valuations significantly above historical norms, leading to increased volatility [1] - Stryker is highlighted as a company that exemplifies this situation, indicating potential concerns regarding its current valuation [1]

Core Viewpoint - Stryker is set to report its financial results for the fourth quarter and full year of 2025 on January 29, 2026, with a press release and webcast scheduled for that day [1][2]. Financial Reporting - The financial results will be announced in a press release at approximately 4:05 p.m. ET on January 29, 2026, which will include summary financial information for the fourth quarter and full year ending December 31, 2025 [1]. - A webcast to discuss these results will take place at 4:30 p.m. ET on the same day, with an archive available on the company's website two hours after the live call [2]. Company Overview - Stryker is recognized as a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3]. - The company impacts over 150 million patients annually, emphasizing its commitment to enhancing patient and healthcare outcomes [3].

Core Business Focus - Intuitive Surgical is a leader in robotic-assisted soft-tissue surgery with its da Vinci platform supporting over 10,800 systems globally and achieving over 20% growth in procedure volumes [2][9] - Stryker operates a diversified MedTech portfolio including orthopedic implants, surgical instruments, and neurotechnology, with robotics playing a smaller role through the Mako system focused on joint replacements [3][5] Robotics Exposure - Robotics is the core growth engine for Intuitive Surgical, generating 85% of total revenues from recurring sources, with high switching costs and a durable competitive moat [4][9] - Stryker's Mako system has performed over 2 million robotic procedures but is limited to orthopedic applications, with growth tied to implant sales rather than a standalone robotics ecosystem [5][6] Revenue Model & Visibility - Intuitive Surgical employs a razor-and-blade model, with recurring revenue growth exceeding 20% supported by procedure growth and utilization, maintaining pro forma operating margins near 39% [7][9] - Stryker's revenue mix includes capital equipment and consumables, with consistent gross and operating margin expansion, but lower margins compared to Intuitive Surgical [8][9] Growth Profile - Intuitive Surgical's growth is driven by deeper penetration in general surgery and geographic expansion, with procedure growth in the high-teens to 20% range [12] - Stryker's growth is steadier, tracking high single digits to low double digits, supported by aging demographics and broad product launches [13] Earnings Estimates - Intuitive Surgical's earnings estimates for the current year are projected at $8.61, with a year-over-year growth estimate of 17.30% [14] - Stryker's earnings estimates for the current year are projected at $13.56, with a year-over-year growth estimate of 11.24% [16] Price Performance & Valuation - Over the past year, Intuitive Surgical has gained 7.5%, while Stryker has declined by 4.3% [17] - Stryker's shares trade at a forward price/earnings ratio of 23.7, significantly lower than Intuitive Surgical's 60.45 [19] Bottom Line - Intuitive Surgical offers greater upside potential due to concentrated robotics exposure and higher margins, while Stryker's diversification and consistent execution make it suitable for stability-oriented investors [23][24]

Core Insights - Parnassus Investments reported that the S&P 500 Index increased by 8.12% in Q3 2025, driven by investor optimism regarding monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, and has a year-to-date return of 9.89% compared to the index's 14.83% [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) experienced a one-month return of -4.86% but gained 5.89% over the last 52 weeks, with a market capitalization of $142.952 billion as of December 22, 2025 [2] - The company reported consolidated revenue of $5.065 billion for Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] Investment Strategy - The Parnassus Core Equity Fund made strategic moves in the Health Care sector by trimming positions in Eli Lilly and Stryker to initiate a position in Boston Scientific Corporation, citing its first-mover advantage and robust clinical data as key growth drivers [3] - Management's focus on disciplined R&D and M&A has led to organic sales growth and margin expansion, positioning Boston Scientific for durable growth [3]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to find those with sustainable growth potential [4] Momentum Score - The Momentum Style Score identifies trends in stock prices and earnings outlooks, helping investors time their positions effectively [5] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with attractive value, strong growth forecasts, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks (4 or 5) should be avoided, even if they have high Style Scores, due to declining earnings forecasts [10] Company Spotlight: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics [11] - The company has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a Growth Style Score of B indicating an expected year-over-year earnings growth of 11.2% for the current fiscal year [12] - Recent upward revisions in earnings estimates and a positive earnings surprise average of +2.9% make Stryker a notable option for growth investors [12][13]

Core Viewpoint - Stryker has announced a quarterly dividend increase to $0.88 per share, reflecting a 4.8% rise compared to the previous year and quarter [1][2]. Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics, impacting over 150 million patients annually [3].

Core Viewpoint - Stryker has appointed Spencer Stiles as President and COO, effective January 1, 2026, to enhance growth and leverage its portfolio [1][2] Group Leadership Changes - Spencer Stiles, a 27-year veteran of Stryker, will lead global businesses, strategy, and M&A, bringing extensive experience from his previous role as Group President of Orthopaedics and Spine [2][3] - Dylan Crotty will succeed Stiles as Group President of Orthopaedics, having spent 27 years at Stryker and previously serving as President of Instruments [3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [4]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating better performance potential [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [4] Momentum Score - Assesses stocks based on price trends and earnings outlook, helping investors capitalize on upward or downward movements [5] VGM Score - Combines all three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth, and momentum [6] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988 [7] - There can be over 800 stocks rated 1 or 2, making it essential to utilize Style Scores for better selection [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: Stryker (SYK) - Stryker is a leader in medical technology, generating approximately 60% of sales from MedSurg & Neurotechnology and 40% from Orthopaedics [11] - The company has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a strong Momentum Style Score of A [12] - Recent upward revisions in earnings estimates indicate positive growth potential, with the Zacks Consensus Estimate for fiscal 2025 at $13.55 per share [12][13]

Core Insights - Stryker is hosting its 2025 Investor Day, indicating a focus on future growth and strategic initiatives [1] - The event features a diverse lineup of speakers from various business segments within Stryker, suggesting a comprehensive overview of the company's operations and future plans [1] - The agenda includes a product fair, providing attendees with an opportunity to engage with company leaders and learn more about Stryker's offerings [1] Event Logistics - The presentation is scheduled to last approximately 2.5 hours, followed by a 15-minute break [1] - In-person attendees will have the chance to participate in a product fair across the parking lot [1]